Peritoneal Malignant Mesothelioma
Associated Genetic Biomarkers
NCI Definition: An aggressive malignant mesothelioma that arises from the peritoneum. Patients usually present with abdominal pain and ascites. 
There are 5 clinical trials for peritoneal malignant mesothelioma, of which 5 are open and 0 are completed or closed. Of the trials that contain peritoneal malignant mesothelioma as an inclusion criterion, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open).
NF2 is the most frequent gene inclusion criterion for peritoneal malignant mesothelioma clinical trials .
Hpn536, mk-4830, and avelumab are the most common interventions in peritoneal malignant mesothelioma clinical trials.
Significant Genes in Peritoneal Malignant Mesothelioma
NF2 is an inclusion eligibility criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.